Abiraterone is an oral analog of pregnenolone that further reduces androgen levels in CRPC tissues by inhibiting CYP17, a key enzyme in the process of androgen synthesis. It has shown good efficacy and safety in phase I-II clinical studies. In a phase III registration study (COU-AA-301), 1195 patients with progressive mCRPC previously treated with docetaxel were randomized 2:1 to the abiraterone (1000 mg/d) + prednisone group and the placebo + prednisone group, with the primary endpoint being OS. All secondary endpoints such as PSA efficiency were also better in the abiraterone group, and salt corticosteroid-related side effects such as water retention, hypertension, and hypokalemia were more common in the treatment group. Based on the results of the COU-AA-301 study, the FDA approved abiraterone + prednisone for mCRPC patients with disease progression after docetaxel use.